Skip to content
Open access

Epigenetic silencing of PDLIM4 promotes colorectal cancer by impairing BTF3 autophagic degradation and activating PI3K/Akt signalling

Oct 2026 · Clinical and Translational Medicine · Vol 16 · 0 citations · 42 references
Medicine

TL;DR

DNMT3A‐mediated silencing of PDLIM4 is an early epigenetic event that facilitates CRC progression and the potential of PDLIM4 methylation as a non‐invasive CRC biomarker is supported.

Abstract

Abstract Background Epigenetic silencing of tumour suppressor genes is a pivotal early event in colorectal cancer (CRC) pathogenesis. PDZ and LIM Domain 4 (PDLIM4) is a member of the PDZ‐LIM family with context‐dependent roles in tumour progression across different malignancies. However, its specific role and epigenetic regulation in colorectal cancer (CRC) remain elusive. Methods We integrated multi‐omics datasets and clinical cohorts to evaluate PDLIM4 expression and promoter methylation. Stool DNA was analyzed to assess the feasibility of non‐invasive detection of PDLIM4 promoter methylation. PDLIM4 knockout and overexpression cell lines were constructed to perform functional assays including proliferation, apoptosis, and stemness. In vivo experiments were validated utilizing xenograft mice or an azoxymethane (AOM)/ dextran sulphate sodium salt (DSS) CRC mouse model with intestinal epithelial cell‐specific overexpression of PDLIM4. Mechanistic investigations were conducted using coimmunoprecipitation coupled with mass spectrometry, RNA sequencing, ChIP‐qPCR and pharmacological rescue experiments. Results We identified a progressive loss of PDLIM4 protein along the normal‐adenoma‐carcinoma sequence, driven by DNMT3A‐mediated promoter hypermethylation, and lower PDLIM4 expression was associated with adverse patient prognosis. PDLIM4 methylation was also significantly increased in stool DNA from CRC patients compared with healthy controls. Mechanistically, genetic ablation of PDLIM4 significantly blunted the therapeutic efficacy of the DNA demethylating agent 5‐Azacytidine against CRC. Functionally, PDLIM4 restoration suppressed CRC cell proliferation and stemness while enhancing apoptosis in vitro, and reduced tumour growth in both AOM/DSS and xenograft models in vivo. At the molecular level, PDLIM4 interacted with BTF3 and promoted its autophagic‐lysosomal degradation, thereby limiting PI3K/Akt signalling, with NTRK2 identified as a potential transcriptional target linking BTF3 to PI3K/Akt activation. Conclusion DNMT3A‐mediated silencing of PDLIM4 is an early epigenetic event that facilitates CRC progression. PDLIM4 suppresses tumour growth by promoting BTF3 degradation, thereby restricting PI3K/Akt signalling. Thus, PDLIM4 methylation may have potential as a biomarker for early CRC detection. Key points DNMT3A‐mediated PDLIM4 promoter hypermethylation is an early event in colorectal tumorigenesis. Restoring PDLIM4 suppresses CRC proliferation and stemness while promoting apoptosis in vitro and in vivo. PDLIM4 promotes the autophagic‐lysosomal degradation of BTF3 and restrains PI3K/Akt signalling. Stool DNA analysis supports the potential of PDLIM4 methylation as a non‐invasive CRC biomarker

Read PDF

Similar papers

Open access Nov 2026

KLHL6 drives colorectal cancer liver metastasis through ubiquitin-mediated degradation of MBD2 that triggers CLDN4 activation

Liver metastasis is the leading cause of death among patients with colorectal cancer (CRC) and remains a major clinical challenge because durable therapeutic options are limited. Metastatic progression depends on extensive transcriptional plasticity, yet how epigenetically silenced prometastatic genes are reactiv...

Wen-Wen Chen, Xiao-Yun Yang, Guochun Lou et al. · 0 citations
Open access Nov 2026

β‐Arrestin1 Promotes Prostate Cancer Progression via Modulating ESRP1‐Mediated Alternative Splicing of CD44

Metastatic prostate cancer (PCa) is a major cause of poor prognosis and mortality, but its underlying mechanisms remain incompletely understood. This study investigated the role of β‐arrestin1 (ARRB1) and its regulation of epithelial splicing regulatory protein 1 (ESRP1)‐mediated CD44 alternative splicing in PCa prog...

Si-Cheng Dong, Min-Lian Pan, Zhi-Qing He et al. · 0 citations
Open access Oct 2026

Circular RNA circERBB2 Promotes Tumorigenesis via the miR‐1587/CBX2 Axis and Epigenetic Silencing of PTEN in Bladder Cancer Cells

Bladder cancer (BLCA) remains difficult to manage because of frequent recurrence and limited effective treatment options. This study investigated the role and mechanism of the ERBB2‐derived circular RNA circERBB2 in BLCA. Public circRNA data sets and a 96‐pair clinical cohort were analyzed to identify dysregulated ci...

Xiang Pan, Xi Chen, Kai-Lai Chen et al. · 0 citations
Open access Oct 2026

LncRNA MALAT1 Targets METTL3 to Orchestrate INPP5B/LRIG2 Signaling and Promote Non‐Small Cell Lung Cancer Progression

In vivo xenograft assays demonstrated that MALAT1 knockdown suppressed tumor growth, which was rescued by METTL3 overexpression, which substantiate the regulatory role of MALAT1‐mediated METTL3 modulation in NSCLC progression through the INPP5B/LRIG2 signaling axis.

Shu-Hong Tian, Fa-Yu Ling, D. Fu et al. · 0 citations
Open access Sep 2026

m5C Reader ALYREF Promotes the Progression of Endometrial Cancer by Activating the XRCC6‐Mediated Wnt/β‐catenin Signaling Pathway

ABSTRACT 5‐Methylcytosine (m5C) is a vital RNA modification that regulates mRNA stability, splicing, and nuclear export. As a key m5C reader, ALYREF promotes tumorigenesis across various cancers; however, its precise role in endometrial cancer (EC) remains unknown. ALYREF expression and clinical significance in EC were...

Lin-Lin Hao, Jian Zhang, Qi Qian et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.